WhatPeptide

Cagrilintide

Cagrilintide is a long-acting acylated amylin analog studied for weight management, acting on amylin receptors in the hypothalamus and brainstem to reduce food intake and promote satiety. It is being developed both as a monotherapy and in combination with semaglutide as CagriSema.

Moderate evidence Investigational Amylin Analog

Written by WhatPeptide Editorial Team · Last updated 2026-03-17

Currently in clinical trials — not yet approved for any indication.

Half-life

Approximately 7-10 days

Dosage range

0.3-2.4 mg once weekly (phase 3 dosing)

Administration

Subcutaneous injection

Research level

Moderate

How Cagrilintide works

Cagrilintide binds amylin receptors (calcitonin receptor complexes with RAMPs) in the area postrema and hypothalamic nuclei, reducing appetite and slowing gastric emptying through pathways complementary to GLP-1 signaling. Its fatty acid acylation confers a long plasma half-life enabling once-weekly dosing. Phase 2 data shows meaningful body weight reductions, with enhanced efficacy observed when combined with semaglutide.

Also known as: AM833, Long-acting amylin analog

Clinical trial efficacy

[object Object]

Research relevance

Fat Loss
Strong research relevance 85

Side effects & safety

Nausea Decreased appetite Vomiting Injection site reactions Pancreatitis (rare but serious) Thyroid C-cell tumors (class-based preclinical signal — rodent data, human relevance uncertain) Potential lean mass loss alongside fat loss

Contraindications

Pregnancy
Personal or family history of medullary thyroid carcinoma
MEN2

Consult a healthcare provider before use if any of these apply to you.

Key studies

FAQ

What is Cagrilintide? +
Cagrilintide is a long-acting acylated amylin analog studied for weight management, acting on amylin receptors in the hypothalamus and brainstem to reduce food intake and promote satiety. It is being developed both as a monotherapy and in combination with semaglutide as CagriSema. Its mechanism of action is supported by moderate clinical and preclinical evidence.
What is Cagrilintide researched for? +
Cagrilintide has the strongest research relevance for Fat Loss. Evidence is supported by moderate clinical and preclinical evidence.
What are the side effects of Cagrilintide? +
Reported side effects include Nausea, Decreased appetite, Vomiting, Injection site reactions, Pancreatitis (rare but serious), Thyroid C-cell tumors (class-based preclinical signal — rodent data, human relevance uncertain), Potential lean mass loss alongside fat loss. Key contraindications: Pregnancy; Personal or family history of medullary thyroid carcinoma; MEN2.
Is Cagrilintide FDA approved? +
Cagrilintide is currently in clinical trials and is not yet approved by the FDA.
How is Cagrilintide administered? +
Cagrilintide is typically administered via subcutaneous route. Researched dosage range: 0.3-2.4 mg once weekly (phase 3 dosing). Half-life: Approximately 7-10 days.

Explore similar peptides

CagriSema

Strong evidence

Amylin/GLP-1 Combination

CagriSema is a fixed-dose co-formulation of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) that demonstrated superior weight loss to either component alone in Phase 3 REDEFINE trials. The combination targets complementary appetite-regulating pathways simultaneously.

Mazdutide

Moderate evidence

GLP-1/Glucagon Agonist

Mazdutide is a once-weekly dual GLP-1 receptor and glucagon receptor co-agonist in late-stage clinical development for obesity and type 2 diabetes, showing significant weight loss in Phase 3 trials predominantly conducted in the Asia-Pacific region. The glucagon component adds hepatic fat mobilization and energy expenditure to GLP-1-mediated appetite suppression.

Retatrutide

Preliminary evidence

GLP-1/GIP/Glucagon Agonist

An investigational triple agonist (GLP-1/GIP/glucagon) with large early-stage weight-loss signals in phase 2 studies.

Semaglutide

Strong evidence

GLP-1 Agonist

A long-acting GLP-1 receptor agonist with robust randomized evidence for glycemic control and body-weight reduction.